We previously investigated the brain eCB system in the TDP‐43 mouse model of FTD and, following the finding of decreased expression of the NAE‐degrading enzyme, FAAH, we treated these mice with a FAAH inhibitor, which improved many behavioral and histopathological alterations linked to FTD in this model [12], effects that we demonstrated in a follow‐up study to be mediated by the activation of CB1 and/or CB2 receptors [14]. This evidence concerns the gene FAAH and frontotemporal dementia.